The effect of dendritic cell mobilization on CD8+ T cell responses to influenza A virus by Shivji, Adil N
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
12-19-2012 12:00 AM 
The effect of dendritic cell mobilization on CD8+ T cell responses 
to influenza A virus 
Adil N. Shivji 
The University of Western Ontario 
Supervisor 
Dr. Mansour Haeryfar 
The University of Western Ontario 
Graduate Program in Microbiology and Immunology 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Adil N. Shivji 2012 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Immunity Commons, and the Immunology of Infectious Disease Commons 
Recommended Citation 
Shivji, Adil N., "The effect of dendritic cell mobilization on CD8+ T cell responses to influenza A virus" 
(2012). Electronic Thesis and Dissertation Repository. 1059. 
https://ir.lib.uwo.ca/etd/1059 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
THE EFFECT OF DENDRITIC CELL MOBILIZATION ON CD8+ T CELL RESPONSES 
TO INFLUENZA A VIRUS  
 
(Spine title: Effect of dendritic cell mobilization on flu-specific T cell responses) 
 
(Thesis format: Monograph) 
 
 
 
by 
 
 
 
Adil N. Shivji  
 
 
 
 
Graduate Program in Microbiology and Immunology 
 
 
 
 
A thesis submitted in partial fulfillment 
of the requirements for the degree of  
Master of Science 
 
 
 
 
The School of Graduate and Postdoctoral Studies 
The University of Western Ontario 
London, Ontario, Canada 
 
 
 
 
© Adil N. Shivji 2013 
 ii 
 
THE UNIVERSITY OF WESTERN ONTARIO 
School of Graduate and Postdoctoral Studies 
 
 
CERTIFICATE OF EXAMINATION 
 
 
 
Supervisor 
 
 
______________________________ 
Dr. Mansour Haeryfar 
 
Supervisory Committee 
 
 
______________________________ 
Dr. Bhagirath Singh 
 
 
______________________________ 
Dr. Kelly Summers 
Examiners 
 
 
______________________________ 
Dr. Jimmy Dikeakos 
 
 
______________________________ 
Dr. Stephen Barr 
 
 
______________________________ 
Dr. Alexander Timoshenko 
 
 
 
 
 
 
The thesis by 
 
Adil Nazir Shivji 
 
entitled: 
 
The effect of dendritic cell mobilization on CD8+ T cell responses to 
influenza A virus 
 
is accepted in partial fulfillment of the 
requirements for the degree of 
Master of Science 
 
 
 
______________________                        _______________________________ 
         Date    Chair of the Thesis Examination Board 	  
 iii 
 
ABSTRACT 
Influenza A viruses (IAV) cause respiratory infections with potentially catastrophic 
consequences. Neutralizing antibodies towards surface proteins of IAV prevent reinfection. 
However, mutations in these proteins allow the virus to evade these antibodies. Enhancing 
cytotoxic T cell-mediated immunity has been proposed as an attractive strategy to combat 
flu. Recombinant human FMS-like tyrosine kinase 3 ligand (FL) is known to mobilize 
dendritic cells (DCs) in mice. Given that DCs are the most potent antigen-presenting cells, I 
hypothesized that their mobilization by FL will improve the CD8+ T cell response to IAV. 
Quantification of CD8+ T cell responses to IAV epitopes by intracellular cytokine staining 
revealed that FL treatment can indeed increase the frequencies and absolute numbers of 
mouse T cells specific for select IAV epitopes. Additionally, FL treatment increased the 
killing function of IAV-specific T cells. My results suggest that FL may exert a therapeutic 
benefit in the context of flu infection. 
 
 
 
KEYWORDS: influenza A virus, dendritic cells, adaptive immunity, antiviral immunity, 
immunodominance, recombinant human FMS-like tyrosine kinase 3 ligand, CD8+ T cell 
responses  
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1.1 Influenza A Virus 
1.1.1 Introduction  
  Responsible for illness, hospitalization and death, the influenza virus is an 
infectious agent that has threatened the health of humans for centuries (1).  A member of 
the Orthomyxoviridae family, genus Orthomyxovirus, influenza can be categorized into 
three classes, A, B and C (1, 2). Influenza A viruses (IAV) are single stranded negative-
sense ribonucleic acid (RNA) viruses, and are of specific importance as they are the only 
class fit to readily colonize within humans (3, 4). Given this, IAV imposes tremendous 
health and economic costs on individuals, groups and countries (5). This can occur 
locally through epidemics although IAV also has the potential to evoke worldwide 
pandemic disease (4).  
  IAV can be further categorized into serotypes designated based on the expression 
of two proteins known as hemagglutinin (HA) and neuraminidase (NA), which are 
distributed on the viral surface in a 5 to 1 ratio, respectively (6). HA can bind to 
glycophorin via sialic acid residues, which is present on the surface of a variety of host 
cells, including those found in the upper respiratory tract. HA is essential for IAV 
infection as it allows attachment and eventual entry into host cells (8). On the contrary, 
NA is an enzyme that cleaves sialic acid groups which allows for detachment from the 
host cell (9). Currently, there exits sixteen primary subtypes for HA (H1-H16) and nine 
primary NA subtypes (N1-N9) (5, 10); therefore many arrangements or serotypes of IAV 
are possible. However, only certain IAV subtypes, mostly H1, H2, H3, N1 and N2 are 
prevalently in circulation in the human population (10).  
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1.1.2 IAV Structure and Proteins 
  The influenza A viral genome consists of eight linear single-stranded RNA 
spanning nearly 13.5 kilobases (kb) (11, 12). This genome encodes for eleven proteins, 
with each protein providing an essential feature in facilitating the spread of the virus (13, 
14). There are 3 membrane-anchored proteins: HA, NA and matrix protein 2 (M2), which 
is a transmembrane ion channel protein. There are three subunits of the viral polymerase: 
acid polymerase (PA), basic polymerase 1 (PB1) and basic polymerase 2 (PB2). In 
addition, there are two structural proteins: nucleoprotein (NP), which binds viral RNA to 
form stable ribonuceloproteins and target these for export from the host nucleus to 
cytosol, and matrix protein 1 (M1).  Furthermore there are two non-structural proteins: 
non-structural protein 1 (NS1) and non-structural protein 2 (NS2). PB1-F2, the latest 
protein discovered, is responsible for binding to the host mitochondria and sensitizing the 
cell to apoptosis (13 – 15).  
 
1.1.3 Evasion Strategies 
  IAV has been a constant burden, both socially and economically (1). This is due 
to the fact that this dynamic virus is continuously evolving and finding new ways to 
evade effective treatments (1). IAV undergoes two kinds of antigenic variation; antigenic 
drift and antigenic shift. Antigenic drift occurs routinely, while antigenic shift occurs 
infrequently (10, 16).  
  Antigenic drift refers to small, gradual changes that occur via point mutations 
caused by selective immune pressure (10). This pressure causes mutations in the genes 
responsible for the natural assembly of the main surface proteins: HA and NA (10, 17). 
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These unpredictable mutations readily produce viral strains with the ability to escape 
recognition by previously produced antibodies (4, 17). This process works as follows: an 
individual is infected with a specific influenza strain to which an antibody response is 
mounted. Upon re-infection with the same strain, antibodies circulating within the body 
will bind specifically to the same HA and NA proteins and eliminate the virus, resulting 
in no symptoms (16). However, if IAV undergoes antigenic drift, this once effective 
immune response can no longer recognize the same HA and NA proteins, hence resulting 
in infection (16, 18, 19). This is the main reason why humans can be seriously infected 
with IAV more than one time (18, 19). This constant need for protection is the motivation 
behind formulating new influenza vaccines every year (18). On the positive side, these 
new subtypes are still related to their predecessors internally and therefore can still be 
subjected to CD8+ T cell recognition (1, 10, 19).  
  While antigenic drift is a minor change to the IAV genome, antigenic shift refers 
to a sudden major change, which has the ability to produce a novel IAV subtype (18, 19). 
This new subtype contains antigens that are distinct from those of previous strains and is 
not currently circulating within the population (18). Antigenic shift can occur in two 
ways. Either through direct animal-to-human transmission or through the mixing of IAV 
strains from both species (18, 19). Mixing of the genetic materials from different viral 
strains resulting in the production of a novel strain is termed genetic reassortment (18). 
This reassortment can cause major changes in the surface proteins, HA and NA, and in 
the internal proteins such that the virus is no longer recognized by the host immune 
system at all (18, 20). If history is any indication, humans have had hardly any immunity 
to these reassorted viruses (18, 20). As such, these viruses have the potential to cause 
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pandemics (20, 21). A global influenza pandemic can occur if the following three 
conditions are met: 1) a new subtype of IAV is introduced into the human population; 2) 
the virus causes serious illness; and 3) the virus has the ability to spread easily from 
human to human (21). A good example of a recent antigenic shift, which could have 
resulted in a global influenza pandemic, occurred in Hong Kong in 1997 (22). A few 
individuals were infected with a novel IAV strain from infected chickens. Mortality in 
these individuals was significant as 6 out of 18 infected individuals died. Authorities in 
Hong Kong ordered the mass killing of 1.5 million chickens, after which no others were 
infected, as the virus (H5N1) did not spread easily from person to person. Thus a possible 
pandemic was fortunately avoided. Nevertheless, we will not always be this fortunate 
(22).  
 
1.1.4 Impacts on Public Health 
  The H3N2, H1N1 and H1N2 subtypes of the virus are currently co-circulating 
within the human populations (23, 24). IAV causes global health issues and life-
threatening infections resulting in roughly half a million deaths per year (18, 21).  
According to the Center for Disease Control and Prevention (CDC), in the United States 
alone, roughly 5-20% of the population is annually infected resulting in 200,000 
hospitalizations and 36,000 deaths. Not only does IAV cause serious public health issues, 
but it also can cause serious economic problems. In developed countries, IAV infections 
can result in many sick days and productivity losses (18). In addition, during the peak 
infection periods, community clinics and hospitals can be overwhelmed when it comes to 
resources and ability to treat their patients (18). Taking both of these into account, the 
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estimated economic burden on the United States every year from IAV is roughly 12-14 
billion dollars (18). Health and economic issues caused by IAV will be ruled trivial if a 
novel IAV strain with the ability to trigger a pandemic is discovered (20, 21, 24).  
  A pandemic can occur if a novel IAV subtype emerges via antigenic shift and can 
effectively infect and spread among the human population who lack the appropriate 
immunity to fight this new subtype (16, 18, 19, 20, 21, 24). Even more concerning has 
been the reports that interspecies transmission of IAV from avian species to humans has 
increased significantly in the past 20 years (25). Fortuitously, the World Health 
Organization (WHO) has determined that no IAV strain that has crossed the interspecies 
barrier has been able to spread efficiently from human to human. However, if these avian 
or swine influenza viruses are able to undergo genetic reassortment with the human IAV, 
they could easily adapt a method allowing for efficient transfer from individual to 
individual (24, 25). A pandemic of this nature has been estimated to have the capacity to 
cause greater than 100 million deaths worldwide (24). The IAV pandemic of 1918, 
known as the “Spanish Flu”, instigated from an adaptation of an avian IAV to human, 
caused the death of roughly 50 to 100 million people (24).  
  The best way to prepare for this inevitable event are to maintain general health 
care practices and perhaps also importantly to boost host immune responses to viral 
infections. In 2009, the “Swine Flu”, which originated from a novel IAV of swine origin, 
was the latest IAV pandemic (26). According to WHO statistics, since April 2009, the 
virus has killed more then 18,000 people. However, there were many deaths in Africa and 
Southeast Asia that were uncounted for. Experts now agree roughly 295,000 individuals 
were killed by this novel IAV strain (27). This latest threat is an excellent example of the 
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problems that surround the emergence of a new strain. Vaccination is the traditional 
strategy used for many years to prevent influenza infections, but its success is not 
complete. Predictions of scientists and successful matching of the vaccine antigen with 
the naturally occurring antigens determine the success of this prevention strategy. After 
infection, the most effective method to clear the pathogen would be to increase viral 
clearance though a more efficient antiviral cellular immune response (36). The effective 
clearance of viral particles would diminish the spread of the virus and significantly 
reduce the threat of future pandemics.  
1.2 CD8+ T cell Activation 
  CD8+ T cells, otherwise known as cytotoxic T lymphocytes (CTLs) in their 
activated state, are a crucial subset of T lymphocytes whose principal function is to 
recognize and eliminate virally infected host cells, tumor cells and other damaged cells 
(28, 29). Specifically for this project, the interest lays in the ability of CD8+ T cells to 
participate in an adaptive immune response to intracellular viral pathogens. Naïve CD8+ 
T cells are only activated by dendritic cells (DCs) (30 – 32). DCs are located in the blood 
and peripheral tissues and monitor the body for possible antigenic material (33). DCs take 
up viruses directly into their cytosol either through phagocytic receptors or through direct 
viral infection (36). Once inside the cytoplasm, the viruses use the host protein machinery 
to create their own proteins (34, 36). Host cell proteasomes process these viral proteins 
and break them down into smaller peptides (34). These peptides are then picked up by 
transporter associated with antigen processing (TAP) proteins, which are embedded in the 
membrane of the endoplasmic reticulum (ER) (35). TAP proteins effectively transport 
these antigenic peptides into the ER of the infected cells, where they compete with self 
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peptides for loading onto major histocompatibility complex (MHC) class I molecules (34, 
36). The MHC class I:peptide complex is then transported to the surface of the DC. Once 
there, the MHC class I:peptide complex will only bind the T cell receptor (TCR) specific 
for this complex (34, 36). The recognition of the MHC class I:peptide complex by the 
TCR is known as signal 1 for the activation of antigen-specific CD8+ T cells leading to 
their differentiation into effector CTLs (34, 36).  
  The successful activation of naïve T cells requires a second signal, which is a co-
stimulatory signal provided by the same antigen-presenting DC (36). Glycoproteins B7.1 
(CD80) and B7.2 (CD86) usually found as a homodimeric compound are expressed on 
the surface of DCs (37). They interact with two receptors on T cells, CD28 and CTLA-4 
(34, 36). Binding of B7 to CD28 is crucial for the clonal expansion of these naïve T cells 
(38), while binding to CTLA-4 negatively regulates the proliferation of already activated 
T cells upon exposure to their antigen (39).  
  Of all antigen-presenting cells (APCs), DCs are thought to be the most proficient 
at priming naïve T cells for a variety of reasons. While circulating within the body and 
resident in tissues, DCs are present in an immature state (iDCs) where they can 
effectively trap and process antigens (33). Once DCs have taken up a viral protein or 
have been infected by a virus itself, they migrate to regional lymph nodes (33). During 
the migration period, these immature DCs undergo a maturation process, which leads to a 
decline in their antigenic uptake and processing ability (33, 36). However, there is an 
enhancement in their ability to present antigens due to increased surface expression of 
MHC class I and co-stimulatory molecules necessary to activate naïve T cells (33, 36). In 
addition to the CD80 and CD86 molecules, CD83 is also upregulated on DCs during 
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maturation (40). CD83 has been shown to influence the antigen-specific activation of T 
cells by mature dendritic cells (mDCs) (40).  
  Mature DCs have the ability to bind to naïve T cells in a very efficient manner. 
(42, 43). This occurs through interactions between lymphocyte function-associated 
antigen 1 (LFA-1), intercellular adhesion molecule 3 (ICAM-3) and CD2 on the T cell 
and ICAM-1, ICAM-2 and DC-SIGN on the DCs (43). In particular, the binding of 
ICAM-3 to DC-SIGN is unique to DCs and T cells (42). This interaction promotes the 
binding of these two cells creating a perfect “immunological synapse”.  This has been 
shown to be crucial to providing enough time for T cells to sample a large number of 
MHC molecules on the APC for the presence of their specific peptide (42).  
 Once activated by the appropriate signals, T cells proliferate and differentiate into 
effector CTLs with the help of the cytokine interleukin-2 (IL-2) (34). CTLs release 
various cytokines such as IFNγ and tumor necrosis factor (TNF), in addition to various 
cytotoxic effector molecules such as perforin and granzymes (36, 43, 44). Perforin 
creates pores in the plasma membrane of target cells to allow granzymes to enter, thus 
starting a cascade eventually leading to apoptosis (programmed cell death) of virally 
infected cells (43, 44). Upon activation, CTLs express the surface protein Fas ligand 
(FasL), which when bound to Fas (CD95) found on target cells induces apoptosis (43 – 
45). The upregulation of these effector molecules is required for elimination of infected 
cells (45).  
 
1.3 Immunodominance 
  IAV has the ability to provide tens of thousands of potentially immunogenic 
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peptides, but CD8+ T cell immune responses are always directed towards a few specific 
peptides (46 - 49). Within this population of peptides, there are those highly 
immunogenic peptides, termed “immunodominant” determinants (IDDs), and other 
“subdominant” determinants (49). This concept is known as immunodominance (46 – 
49). CD8+ T cell responses are managed by a restricted number of TCRs that are antigen-
specific. Those clones with TCRs that are specific for IDDs skew the CD8+ T cell 
response towards these specific antigens while those CD8+ T cells specific for 
subdominant epitopes elicit a much more modest immune response. From the variance in 
response to these immunogenic peptides comes the concept of an immunodominance 
hierarchy (46, 49).  
  This immunodominance hierarchy arises from an intricate combination of factors, 
which encompass several aspects of CD8+ T cell immunology (46, 48, 49). This includes: 
1) generation and regulation of the CD8+ T cell repertoire via positive and negative 
selection (50, 51, 54), 2) interaction of CD8+ T cells with APCs (52), 3) abundance of the 
antigenic source protein within APCs (53), 4) frequency and specificity of TAP transport 
of peptides (54), 5) peptide affinity for MHC class I molecules (54), 6) signaling involved 
in CD8+ T cell activation (53) and 7) immunodomination, which refers to the ability of 
IDD-specific T cells to suppress subdominant T cell responses (46, 49). 
  Even though the above factors have been implicated in ID, this phenomenon is 
not well completely understood. However, its importance in the development of a 
therapeutic vaccine against viral infections should not be overlooked. CD8+ T cells 
cannot prevent flu infections, but they can make a major contribution in eradicating viral 
infections (49, 55). Given this, it is important to understand how immune responses might 
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be altered by different treatments.   
  The immunodominance hierarchy of IAV-specific CD8+ T cells in mice has been 
studied intensely. As mentioned earlier, the IAV genome contains eight linear RNA 
strands and encodes several proteins (11-14). As such, the immunodominance hierarchy 
of CD8+ T cells that are specific for well-defined peptides has been established in the 
IAV system (50, 56, 57). When C57BL/6 (H-2b) mice are infected with IAV, peptides 
NP366 and PA224, which originate from the viral nucleoprotein and acid polymerase, 
respectively, elicit the largest CD8+ T cell response (50, 56). Less robust CD8+ T cell 
responses are also detectable against subdominant epitopes [in order of decreasing CD8+ 
T cell response: PB1-F262, PB1703, PB2198, NS2114, and M1128 (50, 56)]. When Balb/c (H-
2d) mice are infected with IAV, CD8+ T cell responses are against different viral peptides 
than C57BL/6 (H-2b) mice due to their differing MHC backgrounds. Given this, in Balb/c 
mice, the immunodominant peptide NP147 elicits the greatest CD8+ T cell response (50, 
57).  Weaker responses are found towards the other subdominant epitopes (in order of 
decreasing CD8+ T cell response); PB2289, HA518, NP39, NP218 and HA462 (50, 57). The 
order of these responses is highly conserved among the CD8+ population; however, 
changing the immunodominance hierarchy might be useful in the development of an 
effective therapeutic vaccination (46, 49 – 55).  
 
1.4 Dendritic Cells 
1.4.1 Origin and Subsets 
  To trace the lineage of dendritic cells is not simple. This multifaceted lineage 
contains several subsets and various maturation stages (67 – 69). DCs develop from one 
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lymphoid precursor and one myeloid precursor (67 – 69). It has been shown that when 
lymphoid precursors are transferred into irradiated mice, T cells, natural killer (NK) cells, 
B cells and DCs can develop (70, 71). The myeloid DCs were first discovered in in vitro 
studies where isolated myeloid precursors gave rise to DCs with the addition of the 
cytokine granulocyte/macrophage colony-stimulating factor (GM-CSF) (72, 73). Both 
myeloid and lymphoid DCs originate in the bone marrow, but eventually migrate to non-
lymphoid tissues in the body and into peripheral lymphoid organs (67, 74).  
  For simplicity, two broad classes of DCs will be define in this thesis: conventional 
dendritic cells (cDCs) and plasmacytoid dendritic cells (pDCs) (36, 67). cDCs are 
dendritic cells that are known to participate directly in antigen presentation and 
subsequent activation of naïve CD8+ T cells (36, 75, 76). Although several subsets of 
cDCs exist, all subsets have the ability to process and present antigen in an efficient 
manner (36). cDCs express numerous cell surface markers including high levels of 
CD11c (77), a type I transmembrane protein and B7 (described previously). Conversely, 
pDCs secrete significant amounts of type I inteferons (IFN) such as IFNα and IFNβ, but 
apparently do not have an active role in the activation of naïve CD8+ T cells (67, 75). 
pDCs express intermediate levels of CD11c on their surface and low levels of B7 – hence 
their inability to optimally activate naïve CD8+ T cells (36, 78). In contrast to cDCs, 
pDCs express CD45R (B220) on their surface, which enables us to distinguish between 
the two subsets (79).  
1.4.2 Role of Dendritic Cells in Anti-viral Immunity 
  DCs, which originate from bone marrow, are present in non-lymphoid tissues as 
immature dendritic cells (iDCs) (36, 80). This includes areas such as the skin, nose, lungs 
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and the blood (36). iDCs are unable to activate naïve T cells, but have high endocytic 
activity (36, 80).  iDCs are constantly surveying the environment for antigens with the 
mission of sampling a pathogenic antigen that may prove detrimental to the body (36). 
When a pathogen such as IAV is encountered, DCs may release certain cytokines such as 
IFNα (36, 81, 82). The release of this cytokine causes the activation of other innate 
effector cells such as eosinophils and macrophages (36). In addition to secreting 
cytokines, iDCs have the ability to take up and present antigens to adaptive effector cells. 
DCs are very important APCs as they are the only cell type to induce a primary (initial 
exposure to pathogen) CD8+ T cell response. Viruses can infect iDCs directly or be taken 
up by macropinocytosis or phagocytosis (36). After the uptake of an antigen, DCs 
undergo maturation which results in the upregulation of chemokine receptor 7 (CCR7). 
This chemokine induces the relocation of DCs from the blood into the lymphatic 
system/lymph node (36, 83). As DCs mature, they become more potent in activating T 
cells, but decrease their ability to pick up antigens. As explained above, once in the 
lymph node, these mature DCs have the ability to activate antigen-specific CD8+ T cells 
(36). Once activated, CD8+ T cells leave the lymph node and enter circulation, migrating 
towards sites of infection or injury, where they lyse infected cells (36).  
cDCs are clearly important in the activation of naïve CD8+ T cells, but pDCs also 
have an important role in antiviral responses. pDCs express Toll-like receptor (TLR)-7 
and TLR-9, which are important in the recognition of single standard RNA viruses and 
DNA viruses, respectively (36, 84). Upon recognition of the pathogen, these cells secrete 
large amounts of type I interferons (IFNα and IFNβ) (36, 84). The release of these 
14 
 
cytokines stimulates an extensive antiviral response in somatic cells, and leads to DC 
maturation (36).  
1.5 FMS-like Tyrosine Kinase 3 Ligand (FL) 
1.5.1 FL ligand Background 
  Flt3 ligand (FL) is a cytokine known to stimulate proliferation and differentiation 
of stem cells and progenitor cells (58 – 61). Genes encoding FL have been found on a 
section of mouse chromosome 7 and human chromosome 19q13.3 (62). The ligand, 
which has been cloned for both mouse and human, is a soluble protein (61, 62). The size 
and structure of the ligand are strikingly similar to other ligands for tyrosine kinase 
receptors that are involved in the regulation of proliferation and differentiation of cells 
(59). These include colony-stimulating factor 1 (CSF-1) and stem cell factor (SCF). All 
three of these ligands are type I transmembrane proteins that possess a conserved cysteine 
residue stretch in their extracellular domains (59).  
  FL is present in both murine and human systems. The cDNA that encodes FL 
shows a 76% and 72% sequence identity at the nucleotide and amino acid levels in mice 
and humans, respectively (59, 61, 62). Interestingly, mouse and human FLs can stimulate 
the proliferation of cells originating from either species at comparable concentrations 
(59). In fact, multiple studies have used murine FL on human bone marrow cells and vice 
versa (59 – 62). This is in stark contrast to CSF-1 and SCF. Murine CSF-1 does not show 
an effect on human cells, and while human SCF does work on murine cells, it is roughly 
1000 times less active (59).  
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1.5.2 Distribution and Function of FL 
  FL can be found on numerous early progenitor and precursor cells. In addition to 
being present on stem cells, FL is also expressed on both multipotent myeloid progenitor 
cells and multipotent lymphoid progenitor cells (64). Additionally, FL is also expressed 
by various colony-forming unit (CFU) cell types, which are essentially specific precursor 
cells for particular populations (62, 63). Furthermore, FL is also expressed on progenitors 
of NK cells.  
  The receptor for FL is FLT3, which is expressed on stem cells in murine bone 
marrow (60 – 64). Additionally, in humans, FLT3 is expressed on bone marrow-derived 
CD34+ cells. CFU-DC is a term that describes CD34+ precursor cells that eventually 
differentiate into DCs (62, 63). Intriguingly, analysis of FLT3 expression of 
hematopoietic cell lines indicated the presence of the receptor on pre-DC populations 
(63).  
  The primary purpose of FL is to stimulate proliferation and differentiation of 
hematopoietic and progenitor cells in both murine and human models (58 – 66).  
Although there are other ligands that stimulate the proliferation of stems cells, FL is 
unique for multiple reasons. Some important differences include FL’s lack of effect on 
mast cells and its lack of involvement in erythropoiesis (63). However, it does play a role 
in the proliferative stimulation of B cells and DCs.  These results have been obtained in 
in vivo studies using animal models (63). Several studies have shown that delivery of FL 
in mice for 10 days can induce changes in hematopoietic patterns (63, 65).  Furthermore, 
significant morphological changes in murine spleens have been reported including 
splenomegaly (enlarged spleen) and a significantly increased number of large cells with 
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definite DC morphologies (63, 66). Maraskovsky et al. have also shown an increase in 
the number of functionally active in vivo DCs within bone marrow, peripheral blood, 
spleen and lymph nodes after FL treatment in mice (65). 
1.5.3 Impact of FL on DC generation 
  As previously mentioned, DCs are the most effective APC to stimulate naïve T 
cells and induce a primary immune response (30 – 33). Prior to the discovery of FL, DC-
based immunotherapy was relatively ineffective due to the low yield of functionally 
active DCs in the blood or lymphoid tissues (63, 66). For example, GM-CSF has been 
shown to increase the yield of DCs generated in vitro, but no growth factor has been 
identified that increases the quantity of DCs in the lymphoid tissues like FL does (63, 65, 
66). In a study by Shurin et al, FL-treated mice had a significant increase in the yield of 
functionally active DCs in the bone marrow and spleen (63). Functionally active DCs 
were defined as those with the ability to stimulate proliferation of CD8+ T cells (63). 
Given the inherent ability of FL to increase the population of functionally active DCs, its 
assessment as a useful treatment in CD8+ T cell immunotherapy was explored in my 
project.  
1.6  Project Rationale and Aims 
  Vaccination of the general public against IAV is ineffective in inducing protective 
immunity o flu. There are still hundreds of thousands of individuals who are infected 
each year, leading to tremendous health and economic burden. Increasing the antiviral 
CD8+ T cell immune response may potentially be of preventative/therapeutic value. 
 The main goal of this project was to determine if FL treatment can boost the 
magnitude and change the breadth of the anti-IAV CD8+ T cell response as this is 
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unknown at present. Since CTL responses to viral pathogens play a significant role in 
antiviral defense, increasing or modulating this response is a logical approach to enhance 
viral clearance. As mentioned above, DCs play an essential role in the activation of virus-
specific CTLs. Additionally, FL has been shown to increase the DC population found 
throughout the body. Putting these themes together, I hypothesized that with the use of 
FL to mobilize DC populations, we can increase CTL responses to IAV through 
increased priming of naïve T cells by DCs.  
  In order to test this hypothesis, several aims had to be defined. First, FL stock had 
to be tested to ensure its ability to increase the DC population. This was tested in vitro 
and in vivo. If indeed FL did increase the DC population, the next step would be to 
determine if FL treatment (in vivo) can increase the percentage and/or absolute number of 
flu-specific CTLs. In order to determine if FL treatment increases viral clearance, testing 
if FL treatment (in vivo) could increase the cytotoxic killing function of flu-specific CTLs 
needed to be conducted. In addition to exploring the primary immune response, when 
studying IAV, it is important to understand if treatment will help during secondary 
exposure. As such, investigating the role of FL treatment in recall CD8+ T cell responses 
was explored. Finally, the effect of FL treatment in a second mouse strain was studied. 
This study was undertaken to improve our understanding of the overall benefit of FL 
treatment in the context of a CD8+ T cell-based vaccine or other antiviral treatments. 
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Chapter 2: 
Materials and Methods 
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2.1  Mice 
  Adult female C57BL/6 (B6) (H-2b) and Balb/c (H-2d) mice were purchased from 
Charles River Canada Inc. (St. Constant, QC, Canada). Mice were housed in the animal 
care facility at the University of Western Ontario and cared for according to institutional 
and national guidelines.   
2.2 Recombinant Human FMS-like Tyrosine Kinase 3 Ligand  
  Original powdered stock of recombinant human fms-like tyrosine kinase 3 ligand 
(FL) (5 mg/vial) was diluted with sterile water (Sigma, Oakville, ON) and aliquoted into 
individual vials at a final concentration of 50 µg/10 µL. These vials were then stored at -
30°C until needed.  
  In preparation for injections, a FL vial was thawed and transferred into 490 µL of 
PBS giving a final total volume of 500 µL. Mice were subsequently injected via 
subcutaneous (s.c.) injections with 100 µL effectively delivering 10 µg of FL per mouse. 
This treatment regimen was adopted from previously published studies (85). Control 
mice were injected subcutaneously with 100 µL of phosphate-buffered saline (PBS). 
Injections took place for ten consecutive days.  
2.3 Antibodies 
  All monoclonal antibodies (mAbs) were purchased from eBioscience (San Diego, 
CA). Fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD11c (clone N418, 
Armenian Hamster IgG) and allophycocyanin (APC)-conjugated anti-mouse CD45R 
(B220) (clone RA3-6B2, Rat IgG2a) mAbs were used to detect DC populations. In 
intracellular cytokine staining experiments, APC-conjugated anti-mouse CD8α (clone 53-
6.7, rat IgG2a) and FITC-conjugated anti-mouse IFN-γ (clone XMG1.2, rat IgG1) mAb 
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were used to detect surface CD8 and intracellular IFN-γ, respectively. Anti-CD16/CD32 
or Fc Block (clone 2.4G2, rat IgG2b) was used for the prevention of non-specific binding 
of the above mAbs to Fc receptors.  
2.4 Cell Lines  
2.4.1 DC2.4 
  The DC2.4 cell line is an immortalized immature DC line, originally generated 
from C57BL/6 mice (H-2b) (86). The cell line was created and provided to our laboratory 
by Dr. Kenneth Rock (University of Massachusetts Medical School, Worchester, MA). 
When needed, vials containing DC 2.4 cells that were stored in liquid nitrogen were 
thawed using a 55°C water bath. After centrifugation (Beckman Coulter, Mississauga, 
ON) at 1400 RPM, cells were washed three times in complete RPMI 1640 medium 
(cRPMI): RPMI 1640 containing L-glutamine (Gibco, Grand Island, NY) was 
supplemented with 1 mM sodium pyruvate, 100 units/mL of each penicillin G and 
streptomycin (Sigma), 1 mM of non-essential amino acids (Gibco) and 10% fetal bovine 
serum (FBS) (HyClone, UT, USA). Following washing, DC 2.4 cells were resuspended 
in 10 mL of cRPMI, seeded into a tissue culture flask (Falcon BD, Mississauga, ON) and 
incubated at 37°C and 6% CO2. Cells were sub-cultured into new tissue culture flasks 
until they reached 80-85% confluency.  Given the adherent nature of the DC2.4 cell line, 
trypsin (Gibco) was used to detach cells from the flask surface. Cells were washed, and 
re-seeded into a new tissue culture flask with fresh cRPMI.  
2.4.2 Balb/c 3T3 
  The Balb/c 3T3 cell line was generously provided by Dr. Yong Kang (University 
21 
 
of Western Ontario). 3T3 cells are derived from Balb/c (H-2d) fibroblasts. Thawing and 
seeding into tissue culture flasks followed the same procedure described above. However, 
the medium used for the effective growth of these cells was Dulbecco's Modified Eagle 
Medium (DMEM) (Gibco) supplemented with 10% bovine serum (Hyclone). 3T3 cells 
were incubated at 37°C and 9% CO2. To effectively maintain a healthy cell culture, cells 
were sub-cultured every 7-8 days (80-85% confluency) due to their slower growth period. 
Given the adherent nature of the Balb/c 3T3 cell line, trypsin (Gibco) was used to detach 
cells from the flask surface. Cells were then washed and re-seeded into a new tissue 
culture flask with fresh supplemented DMEM medium.  
2.4.3 P815 cells 
 This H-2d mouse lymphoblast-like mastocytoma cell line was maintained in the 
similar fashion to the 3T3 cell line above. However, unlike the adherent 3T3 cell line, 
these cells are suspended in media and therefore do not require trypsin treatment. These 
cells were used as target cells during the chromium release assay.  
2.5 Viral Peptides 
  The main IAV strain used in this project was the Puerto Rico/8/1934 (PR8) H1N1 
strain, which has been heavily studied and is well characterized. As such, the structure 
and CD8+ T cell immunodominance hierarchies have been well established following the 
infection of C57BL/6 and Balb/c mice with this IAV strain (50, 56, 57).  Peptides are 
named based on the protein they are derived from in addition to the specific numeric 
amino acid locations within that protein. Synthetic viral peptides (Tables 1 and 2) used in 
this project were generously provided to our laboratory by Dr. Jack Bennink and Dr. 
Jonathan Yewdell (National Institutes of Health, Bethesda, MD). These peptides were  
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Table 1. PR8 viral peptides used in this thesis research (Balb/c) 
Determinant  Abbreviation  Restricting MHC Sequence 
NP147-155 NP147 H-2Kd TYQRTRALV 
NP39-47 NP39 H-2Kd FYIQMCTEL 
NP218-226 NP218 H-2Kd AYERMCNIL 
HA462-470 HA462 H-2Kd LYEKVKSQL 
HA518-526 HA518 H-2Kd IYSTVASSL 
PB2289-297 PB2289 H-2Dd IGGIRMVDI 
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Table 2. PR8 viral peptides used in this thesis research (C57BL/6) 
Determinant Abbreviation Restricting MHC Sequence 
PA224-233 PA224 H-2Db SSLENFRAYV 
NP366-374 NP366 H-2Db ASNENMETM 
PB1-F262-70 PB1-F262 H-2Db LSLRNPILV 
PB1703-711 PB1703 H-2Kb SSYRRPVGI 
M1128-135 M1128 H-2Kb MGLIYNRM 
NS2114-121 NS2114 H-2Kb RTFSFQLI 
PB2198-206 PB2198 H-2Kb ISPLMVAYM 
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over 95% pure. All peptides were dissolved in dimethyl sulfoxide (DMSO) and stored at 
-30°C.  
2.6 Viral Inoculation 
  Influenza A viruses used in this project, PR8 and SEQ12, were propagated within 
the allantoic cavity of 10-day-old embryonated chicken eggs. Viral particles were isolated 
from the eggs and aliquoted to a final volume of 1 mL of infectious allantoic fluid per 
glass vial (VWR, Mississauga, ON). These aliquoted viral stocks were then frozen and 
stored at -80°C until use. 
  When determining the effect of FL on primary CD8+ T cell responses to IAV, 1 
mL of PR8 was thawed and added to 1 mL of PBS to give a 1:2 dilution. From this 
mixture, 450 µL was injected into each mouse intraperitoneally (i.p.), which was 
estimated to deliver approximately 600 hemagglutinating units. This dosage has been 
shown to efficiently induce IAV-specific CD8+ T cell responses in mice as previously 
reported (87). Injection of PR8 occurred on day 0 in all experiments.  
  When determining the effect of FL on CD8+ T cell recall responses, mice were 
primed via an i.p. injection of PR8 on day 0 followed by injection of SEQ12 via the i.p. 
route on day 30.  
2.7  In vitro infection of DC2.4 or 3T3 cells for viral antigen presentation 
  To gauge for a representative “overall” antiviral response of all flu-specific CD8+ 
T cells, DC2.4 cells or 3T3 cells were infected with IAV. The following procedure 
outlines the infection methodology. Cells were collected from their respective tissue 
culture flasks and placed in a 15 mL conical tube (Falcon BD). The tube was then filled 
with sterile PBS (Sigma) and centrifuged at 1400 RPM for 4 minutes. After 
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centrifugation, the supernatant was discarded and cells were resuspended in 1 mL of 
PBS. From here cells were counted with the aim to collect 8-10 million cells. After 
another PBS wash, cells were resuspended in 1 mL of PBS. Similar to the preparation for 
inoculation in mice, a two-fold dilution was completed by adding 1 mL of IAV infectious 
allantoic fluid to 1 mL of PBS containing 8-10 million cells. Cells, now in the presence of 
IAV, were incubated for 1 hour at 6% CO2 and 37°C while being constantly mixed via a 
cell rotator. After 1 hour, 6 mL of complete medium was added and cells were left inside 
the CO2 incubator for another 5 hours. After this incubation period, cells were taken out 
and washed three times in complete medium to remove any excess viral particles. Cells 
were now considered infected with IAV and ready to be used in my ICS experiments.   
2.8 Intracellular Cytokine Staining 
  Intracellular cytokine staining (ICS) for interferon IFNγ is a highly sensitive and 
quantitative technique used to determine the frequencies and absolute numbers of 
antigen-specific CD8+ T cells (Figure 1), as it is the primary cytokine produced by 
stimulated CD8+ T cells. The ICS assay was conducted seven days after PR8 inoculation, 
a time point at which antigen-specific CD8+ T cells response are known to be at their 
peak (87).  This method allowed us to precisely examine CD8+ T cell responses to virally 
infected cells, in addition to synthetic peptides corresponding to specific epitopes of IAV. 
  On day seven post-inoculation, spleens and peritoneal exudate cells (PECs) were 
isolated from mice in treatment and control groups (FL and PBS, respectively). The 
spleen was isolated as it is a major peripheral lymphoid organ housing a significant pool 
of CD8+ T cells and represents the systemic immune response to IAV (87). PECs were 
isolated from the peritoneal cavity as they are indicative of a local immune response to 
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i.p. injection.  
 Isolated spleens were individually homogenized in 5 mL of PBS and then 
transferred into a 15 mL Falcon tube. Next, both splenocyte and PEC suspensions were 
centrifuged at 1400 RPM for 4 minutes at 4 °C. The cell pellets were then racked and 4 
ml of ACK lysis buffer (0.15M ammonium chloride, 1.0 mM potassium bicarbonate and 
0.1mM ethylenediaminetetraacetic acid) was added for precisely 4 minutes to eliminate 
erythrocytes. To stop cell lysis, 10 mL of PBS was added to each tube and cells were 
spun once more (same setting as above). The cell pellet was then racked and cells were 
resuspended in 10 mL of complete medium. Large cellular debris, such as fat, was 
removed from the splenocyte suspension by rotating Falcon tubes while transferring the 
cellular suspension into new 15 mL Falcon tubes. After re-centrifugation, both 
splenocytes and pooled PEC suspensions were counted and seeded into a U-bottom, 96-
well polystyrene plate (Falcon BD). Splenocytes were seeded at 2 x 106 cells/well, while 
PECs were seeded at 5 x 105 – 1 x 106 cells/well.  
  Once in their respective wells, medium alone (nil), irrelevant peptide (control) or 
specific synthetic IAV-derived peptides were added.  Peptides were added at a final 
concentration of 500 nM. The irrelevant peptide used was nucleoprotein (NP) 118, which 
is a immunogenic peptide of the lymphocytic choriomeningitis virus (LCMV). This 
peptide is restricted by H-2d. NP118-specific CD8+ T cell responses are not detectable in 
IAV-inoculated mice because the mice were not infected with LCMV. In parallel with 
control and cognate peptides, the in vitro flu-infected cells were added into the wells 
containing bulk splenocytes or PECs to account for an overall anti-IAV CD8+ T cell 
response. Roughly 200,000 flu-infected cells were added per well. Once the peptides and 
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flu-infected cells were added, the plate was placed in an incubator (37 °C; 6% CO2). 
After a two-hour incubation period, brefeldin A (BFA) (Sigma-Aldrich) was added to the 
wells at a final dose of 10 µg/mL. BFA inhibits the transport of proteins from the 
endoplasmic reticulum (ER) to the Golgi and thus leads to the accumulation of IFNγ, 
among other soluble mediators, inside activated in-vivo primed T cells. Cells were then 
placed into the incubator for another 3 to 4 hours after which time they were stained.  
  Following this incubation, cells in the U-bottom plate were spun at 2100 RPM for 
5 minutes. Once confirming the presence of cellular pellets, the supernatant was 
discarded and the plate was gently vortexed to loosen the pellet. 20 µL/well of Fc Block 
was added to prevent non-specific binding of fluorochrome-labeled antibodies to Fc 
receptors. After 20 minutes, APC-conjugated anti-mouse CD8α mAb was diluted in 
PBS/bovine serum albumin (BSA) in a 1:200 ratio. Fifty µL of the diluted antibody was 
added per well via a multi-channel pipette and left on ice for 30 minutes. Cells were then 
washed with PBS and fixed using 1% paraformaldehyde (Electron Microscopy Sciences, 
Hatfield, PA) for 20 minutes at room temperature in the dark. Cells were washed three 
times, and then left to incubate overnight with 50 µL of diluted FITC-conjugated anti-
mouse IFN-γ mAb. The antibody was diluted with cold PBS, which contained 0.1% 
saponin (Calbiochem), whose purpose is to permeabilize the cellular membrane allowing 
the IFN-γ mAb to gain access to the interior of the cell, for instance to the ER. After the 
overnight incubation, cells were washed thrice, resuspended in 200 µL of PBS/BSA and 
transferred to individual fluorescence activated cell sorting (FACS) tubes (Falcon BD) to 
be read by flow cytometry.  
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Figure 1: Intracellular cytokine staining overview. In brief, spleens and PECs were 
harvested from Balb/c mice seven days after PR8 inoculation. Splenocytes and PECs 
were purified and plated in the presence of synthetic IAV-specific peptides in order to re-
simulate in-vivo primed CD8+ T cells. Cells were stained for CD8 and intracellular IFNγ, 
after which samples were read by a FACSCanto II flow cytometer.  
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2.9  Bone Marrow Isolation 
  Balb/c mice were euthanized via cervical dislocation. Bone marrow-derived DCs 
(BMDCs) were generated as previously described (63). In brief, femurs and tibias were 
dissected and placed into a tissue culture dish (Falcon BD) containing PBS. Using 
scissors and forceps the muscle was stripped away eventually isolating the bones. 
Holding the bare bone with forceps, the top and bottom of the bone were cut, exposing a 
hole on each end. A 25G needle (Becton Dickinson) attached to a 10 cc syringe (Becton 
Dickinson) filled with PBS was inserted into one side of the bone and used to flush out 
all marrow cells and particles, directly into a 50 mL Falcon tube until the bone turned 
white and was completely washed out. Once collected, the marrow cells were centrifuged 
for 4 minutes at 1400 RPM. The cells were subsequently racked and treated with ACK 
lysis buffer to remove all erythrocytes. PBS was added to neutralize the buffer, and once 
again the cells were centrifuged. After racking and resuspending the cells in PBS, the 
suspension was filtered through a 40 µm cell strainer (Falcon BD) into a new 50 mL 
Falcon tube to remove non-cellular particles. Cells were centrifuged once again and 
finally resuspended in 2 mL of cRPMI. Cells were counted and adjusted to 1 million 
cells/mL (in complete medium). Four million BM cells (4 mLs) were then transferred 
into each well of a 6-well plate (BD Falcon) and incubated at 37°C and 6% CO2.  
2.10  Flow Cytometry Analysis  
  Cytofluorimetric analyses were performed using a BD FACSCanto II flow 
cytometer (BD Biosciences). A minimum of 1 x 105 events were acquired for splenocytes 
and bone marrow samples, while 5 x 104 events were gathered for each PECs sample. 
After collection, the data was analyzed using FlowJo software (Tree Star, Ashland, OR). 
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  Once events were displayed in FlowJo, using forward and side scatter, all live 
cells were gated on, excluding dead cells. Forward scatter is indicative of cell size, while 
side scatter specifies cellular granularity and/or content complexity. Dead cells have low 
forward and side scatter profiles and are therefore represented in the bottom left corner 
(Figure 2A). Analyzing from the live cell population only, the x-axis was changed to the 
APC-anti-CD8+ stain. The population of live cells expressing CD8 on their surface was 
then specifically gated (Figure 2B). From here, any possible differences in the percentage 
of CD8+ cells due to FL treatment can be noted and analyzed. Expression of intracellular 
IFNγ was then analyzed on the gated live CD8+ cell population. The percentage of CD8+ 
T cells that expressed IFNγ was then calculated (Figure 2C and 2D). IFNγ+ CD8+ live 
cells represent the IAV-peptide-specific CD8+ T cell population in the spleen (or among 
PECs) of treated animals for each individual peptide tested. In order to provide an 
accurate calculation of the response to each peptide, the percentage of nil-treated CD8+ 
IFNγ+ of each spleen (or PECs) was subtracted from the percentage of peptide treated 
CD8+ IFNγ+ for each cognate peptide. Another method used to ensured accuracy and fair 
analyses involved placing the CD8+ IFN-γ+ rectangular gate on only the nil samples first 
(for each individual spleen). The exact locations of the nil gates were then applied to all 
peptides and virus-infected cell samples within their respective spleen or PEC sample.  
2.11 Assessment and Staining of FL-Treated Bone Marrow Cells 
  After bone marrow cells were plated and incubated in a 6-well plate, 200 ng of FL 
was added to each well. Pictures of FL-treated wells and non-treated cultures were taken 
from day 0 to day 6. On day 6, 1 million cells from each well (3 treated and 3 non-
treated) were transferred into six separate 5 mL BD FACS tubes. Two mL of staining  
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Figure 2: Gating strategy employed to identify IAV-specific CD8+ T cells. Each dot 
represents one event. This figure is a representative example of one analyzed sample. A, 
Initially the total live cell population is gated upon. Then, live cells positive CD8 were 
gated on (B). Then, CD8+ gated live cells that co-expressed intracellular IFN were gated. 
C, represents the CD8+ IFNγ+ control population, when cells were incubated in medium 
alone (0.37%). D, represents the CD8+ IFNγ+ population, cells were re-stimulation with 
the NP147 peptide, the most immunodominant peptide epitope of IAV in the Balb/c 
strain.  
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buffer (PBS +1% FCS) was then added into all tubes and centrifuged at 1400 RPM for 4 
minutes. After the spin, each tube was incubated with 20 µL of Fc block for 20 minutes 
on ice to prevent non-specific binding of mAbs. Without washing off the Fc block, 50 µL 
of a master mix containing FITC-anti-CD11c and APC-anti-B220 mAbs diluted in the 
staining buffer was added to each tube. After 30 minutes of incubation in the dark, the 
stained cells were washed twice, once with staining buffer and once with PBS. Cells were 
then fixed, resuspended in 500 µL of 1% paraformaldehyde and read by a FACSCanto II 
flow cytometer. 
2.12 Chromium Release Assay (51Cr release assay) 
  To determine the effect of FL on CTL-mediated killing, a standard 51Cr release 
assay was used. Briefly, splenocytes were isolated using the same methodology explained 
above for my ICS experiments. However, rather than being treated with peptides and 
virally infected cells, these splenocytes were used as effector cells against chromium-
labeled P815 (H-2d mouse lymphoblast-like mastocytoma cells) target cells. These target 
cells, prior to cultivation with effector cells, were labeled with 51Cr and pulsed with each 
specific IAV peptide. After this incubation period, target cells incorporate 51Cr within 
their cellular membrane and present the respective peptide they are pulsed with via MHC 
Class I molecules. An “overall” killing percentage to IAV was determined by using IAV-
infected P815 cells (similar to the in vitro infection done on DC2.4 and 3T3 cells). This 
allows a natural display of peptide antigens on MHC Class I by P815 cells. In the 
presence of the splenocyte pool, effector CD8+ T cells that have seen the IAV peptide 
before will lyse the target cell effectively releasing 51Cr into the supernatant.  
  Effector splenocytes were seeded into a 96-well plate and 104 target cells were 
33 
 
added per well. Cells were plated to provide an effector to target cell ratio of 30:1, 100:1 
and 300:1. The cells were left to incubate together for 9 hours at 37°C and 6% CO2. After 
the incubation period, the supernatant was harvested from each sample and the 51Cr 
release was calculated on a gamma counter. Specific killing by CD8+ T cells was 
calculated using the following formula: !"!!"!"!!" x 100. ER is defined as experimental 
release, which is the authentic 51Cr release from wells containing effector and target cells. 
SR, or spontaneous release, is determined from wells containing target cells with the 
addition of media only. This provides the amount of 51Cr that is naturally released in this 
assay, a simple negative control. On the contrary TR or total release, is determined from 
wells receiving target cells in addition to Triton X-100 (Sigma-Aldrich). Triton X-100 is 
a biochemical reagent that causes the lysis of all cells and serves the purpose of being a 
positive control, indicating the total amount of 51Cr that can be released.  
2.1.3 Statistical Analysis  
  For ICS results, graphed values were adjusted by subtracting background levels of 
IFN-γ. Background levels were obtained from wells receiving only medium. Statistical 
comparisons were performed using Student’s t-test. Error bars represent the standard 
error of the mean. Graphs generated using GraphPad Prism software (GraphPad Prism 
Software, Inc. CA, USA). Significant values p < 0.05 and p < 0.01 are denoted by ∗ and ∗∗
, respectively.  
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Results 
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3.1  The effect of FL on DC generation in vitro 
  Before testing the ability of FL in DC mobilization leading to augmentation of 
antiviral CD8+ T cell responses, as hypothesized, it was necessary to determine the 
effectiveness of the FL stock in expanding DC populations. According to the literature, 
the dosage of FL given should be sufficient to promote the transition of bone marrow 
cells into a DC phenotype (88). Originally, this was tested in vitro, by incubating bone 
marrow cells isolated from Balb/c mice with 200 ng/ml of FL or nil (control), for 6 days.  
The cultured cells were then examined both morphologically and phenotypically for their 
differentiation into DC.  Microscopic pictures of both treated and non-treated cells were 
taken daily (Figure 3). From these pictures, it is evident that bone marrow cells treated 
with FL showed an increase in number compared to the control. In addition, on day 6, 
dendrite projections were evident on FL-treated bone marrow samples. While an apparent  
overall increase in the number of cells and dendritic projections in the FL treatment 
group, this was not sufficient in proving that FL was expanding DC populations. This 
question was answered through staining for CD11c and B220 on day 6 (Figure 4). From 
this in vitro stain, it is clear that FL-treated bone marrow sample contains more CD11c+ 
B220+ cells (2.6% control vs. 12.5% FL treatment), which is indicative of plasmacytoid 
DCs (78, 79). Furthermore, there was an increase in the CD11c+ B220- cell population, 
which represents cDCs (0.36% control vs. 11.6% FL treatment) (77).   
3.2 The effect of FL on DC populations in vivo 
  Although it was reassuring that our FL stock had the ability to expand DC 
populations in vitro, it was essential to test the ability of FL to expand these populations 
in vivo. Therefore, to determine the effectiveness of FL treatment in vivo, Balb/c mice 
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Figure 3: Microscopic pictures of bone marrow cells treated with FL. Isolated bone 
marrow cells (4 x106 cells) were incubated for 6 days either in the presence or absence of 
FL (200 ng/ml).  From day 3 the effect of FL treatment is apparent and leads to formation 
of dendrites that are visible around day 6. Pictures were taken from VWR 
VistamodelVison microscope (model #: 82026-630) at 25x magnification.  
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Figure 4: Contour plot of in vitro cultured Balb/c bone marrow cells. FL-treated and 
untreated bone marrow cells were washed and stained for CD11c and B220 in order to 
test the effectiveness of FL treatment in expanding DC popultions. Gates for each sample 
were individually placed due to a shift in population during reading. Contour plots 
indicate the presence of multiple cells populations rather than individual cells. FL 
treatment leads to an increase in both DC populations in vitro (plasmacytoid and 
conventional).  
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were subcutaneously injected with either FL (10µg in 100µl of PBS) or sterile PBS 
(control) for 10 days as previously described (85). On day 10, three measures were used 
to determine the ability of FL to expand the DC populations. The first measure was the 
ability of FL to increase the spleen size (splenomegaly), which is customary during FL 
treatment (63). Spleens of both FL-treated mice and PBS-treated mice were isolated and 
compared for their size (Figure 5). This picture illustrates that FL treatment did in fact 
lead to splenomegaly. The next step was to determine that this increase in size was due to 
an increase in splenocytes and not due to other possible effects (e.g. increase in the 
amount of fat, fluid, red blood cells, etc.). Once isolated, spleens were homogenized and 
splenic cells were counted. Figure 6 illustrates an increase in the number of cells found in 
FL-treated spleens. Finally, the last step was to determine if the increase in cells was due 
to an expansion of DC populations. Splenocytes were stained using the same mAbs 
(CD11c and B220) (Figure 7). Splenocyte staining clearly showed an increase in both 
CD11c+ B220+ and CD11c+ B220- populations, indicative of an increase in the DC 
compartments.  
3.3 Confirmation of the ID Hierarchy 
  Prior to determining the ability of FL to increase the CD8+ T cell responses to 
various viral epitopes, as hypothesized, it was important to confirm that the IAV ID 
hierarchy does in fact stay consistent in my hands. To determine this, mice were injected 
with PBS subcutaneously for 10 days, mimicking the upcoming FL treatment regimen. 
On day 0, mice were injected with IAV (PR8 strain). Seven days later, a time point at 
which PR8-specific CD8+ T cell responses reach their peak (87) mice were euthanized 
and an ICS assay for IFNγ was conducted on the spleens of these mice. In the literature, 
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Figure 5: Pictures of isolated spleens from FL treated and control Balb/c mice. Mice 
were treated with either FL (10 µg) or PBS for 10 days. On day 10, spleens from all mice 
were isolated and photographed.   
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Figure 6: Absolute numbers of splenocytes from FL-treated and control 
Balb/c mice. Mice were treated with either FL (10µg) or PBS for 10 days. On day 10, 
spleens from all mice were homogenized after isolation. The data represents one 
experiment of three independent experiments. * denotes a significant difference, p < 0.05 
(PBS n=4, FL n=4). 
 
 
 
 
 
Treatment Group
Ab
so
lu
te
 n
um
be
r o
f s
pl
en
oc
yt
es
 (x
 1
06
)
PB
S
FL
T3
L
0
50
100
150
PBS
FLT3L
*
* p < 0.05
41 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 7: The frequencies of conventional and plasmacytoid DCs in the spleen of 
FL-treated and control Balb/c mice. Mice were treated with FL (10µg) or PBS for 10 
days. On day 10, spleens from all mice were isolated and homogenized followed by 
staining for CD11c and B220. 
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previous studies have reported that CD8+ T cell CTL responses to IAV in Balb/c mice are 
favoured towards the NP147 immunodominant peptide (50, 57).  Weaker responses are 
also detectable against so-called subdominant epitopes. These are PB2289, HA518, NP39, 
NP218 and HA462 in order of decreasing CD8+ T cell response they induce. These 
experiments showed that CD8+ T cell response follow this well-established 
immunodominance hierarchy (Figure 8).  
3.4 Frequency of CD8+ cells  
  Prior to determining the absolute number of epitope specific CD8+ T cell 
responses, I had to determine the frequency of CD8+ cells among live-gated splenocytes. 
Figure 9 illustrates that both FL- and PBS-treated mice have the same frequency of total 
CD8+ cells found in their spleen, typically ranging between 12-15%. Therefore, the noted 
increase in the absolute number of epitope-specific CD8+ T cells likely reflects increases 
in splenic cellularity and also importantly to heightened frequencies of epitope-specific 
CD8+ T cells. 
3.5 The effect of FL on frequencies of epitope-specific CD8+ T cells 
  In order to determine if FL has an effect on the percentage of flu-specific CD8+ T 
cells, mice were injected with FL or PBS for 10 days (day -3 to day 7). On day 0, mice 
were injected with IAV (PR8 strain). Mice were then euthanized seven days later, which 
correlates with the peak CTL response to IAV in the literature (89). Immediately after 
sacrifice the ICS procedure for IFNγ was performed on the splenocytes and PECs of all 
mice. Subsequently, samples were acquired by a flow cytometer and CD8+ T cell 
responses were analyzed by FlowJo using the aforementioned gating strategies. After 
gating on CD8+ IFNγ+ populations, the percentage of IFNγ+ cells from the CD8+ 
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Figure 8: ID hierarchy in CD8+ T cell responses to IAV (PR8 strain) in Balb/c mice. 
Mice were inoculated with IAV and seven days later an ICS for IFNγ was conducted. 
Specific peptides corresponding to IAV epitopes were added to splenocytes. CD8+ cells 
were gated on, followed by determination of IFNγ+ producing cell frequencies among 
CD8+ cells. Error bars represent standard errors of the mean calculated for 4 mice. The 
observed hierarchical pattern was reproducible in all ICS experiments in this study. 
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Figure 9: Frequency of CD8+ cells from live splenocytes of Balb/c mice. Mice were 
treated with FL (10 µg) or PBS for 10 days (day -3 to 6). On day 0, all mice were injected 
with IAV (PR8 strain). On day 10, mice were euthanized and an ICS was conducted. FL 
treatment did not alter the frequency of CD8+ cells. This data represents the reproducible 
trend from one of multiple experiments typically using 4 mice per group. 
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population was graphically represented (Figures 10 and 11). Figure 10, which reflects the 
percentage of epitope-specific CD8+ T cells in the spleen, illustrates a clear increase in 
splenic response for several epitopes in FL-treated mice. Additionally, FL treatment 
resulted in an increase in the percentage of CD8+ T cells responding to flu-infected cells. 
In fact, the increase in response for FL-treated mice in three of the six peptides reached 
statistical significance (p < 0.05). Furthermore, it is important to note the consistency of 
the immunodominance hierarchical pattern. There was no change in the IDD, as NP147 
remained the most immunogenic peptide. In addition, the other subdominant peptides 
followed the established hierarchy. The data presented in figure 10 is a compilation of 
three separate ICS experiments. In total, 9 PBS-treated mice and 12 FL-treated mice were 
analyzed. Figure 11, which illustrates the CD8+ T cell response in the peritoneal cavity, 
as a picture of the local response, shows a surprising decrease in percentage of CD8+ T 
cell response across all epitopes in the FL treatment group. Once again, the ID pattern did 
stay constant for both treatment groups. The data represented in this figure is the average 
of three separate ICS experiments, where PECs were pooled from all mice from the same 
treatment group. Note that it was difficult to conduct ICS assays on PECs obtained from 
each individual mice because many thousands of cells cannot be recovered from the 
peritoneal cavity – hence my experiments on pooled PECs for each treatment group.   
3.6 The effect of FL on absolute number of flu-specific CD8+ T cells 
  The absolute number of epitope-specific CD8+ T cells was determined by taking 
into consideration the number of cells per each spleen, the percentage of CD8+ cells 
among live splenocytes and the frequencies of epitope-specific CD8+ T cells (i.e. CD8+  
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Figure 10: Frequencies of CD8+ IFNγ+ cells in the spleens of FL-treated and control 
Balb/c mice. Mice were treated with FL (10 µg) or PBS for 10 days (day -3 to 6). On day 
0, all mice were injected with IAV (PR8 strain). On day 10, mice were euthanized and an 
ICS was conducted on splenocytes to determine the percentage of the double positive 
(CD8+ IFNγ+) cells, which represents epitope-specific CD8+ T cells. * denotes a 
significance difference, p < 0.05 (PBS n=9, FL n=12).  
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Figure 11: Frequencies of flu-specific CD8+ T cells among PECs of FL-treated and 
control Balb/c mice. Mice were treated with FL (10 µg) or PBS for 10 days (day -3 to 6). 
On day 0, all mice were injected with IAV (PR8 strain). On day 10, mice were 
euthanized and an ICS was conducted to determine the percentages of peritoneal epitope-
specific  (CD8+ IFNγ+) T cells. N = 3 (three separate experiments, pooled PECs).   
 
 
48 
 
IFNγ+ cells). These double positive populations, which represent epitope-specific CD8+ T 
cells, are illustrated in a graphical representation (Figure 12 and 13). Figure 12 shows an 
increase in the absolute number of splenic CD8+ IFNγ+ cells across all epitopes and flu-
infected cells as a result of FL treatment. In fact, two epitopes and the overall response, 
as determined by using flu-infected cells in lieu of individual peptides, reached statistical 
significance (p < 0.05). This is consistent with the data shown in Figure 13, which 
displays an increase in the absolute number of peritoneal CD8+ IFNγ+ cells in FL-treated 
mice. It is of interest to note that although the percentage of CD8+ T cells decrease in 
PECs after FL treatment, the absolute numbers of effector cells actually increase due to 
FL treatment. 
3.7 The effect of FL on CTL effector function 
  The primary function of CTLs is to kill virally infected cells. In order to test if FL 
treatment enhances CTL mediated killing, the gold standard test of chromium release (as 
mentioned in the Material and Methods) was used. Target cells were incubated with 
individual peptides in parallel and labeled with 51-chromium simultaneously. During this 
incubation period viral peptides are presented on the surface of these cells via MHC class 
I molecules. Figures 14 and 15 depict the killing ability of CTLs isolated from PBS and 
FL-treated mice.  The y-axis, “% killing”, was calculated using the formula found in the 
Methods section, which takes into consideration total and spontaneous chromium release. 
Figure 14 specifically looks at the killing ability towards cells that present the most 
immunodominant peptide (i.e. NP147). As expected, the killing percentage towards cells 
that presented NP147 was higher than those presenting subdominant peptides (Figure 15), 
regardless of treatment. FL treatment significantly increased the killing ability of CTLs  
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Figure 12: Absolute number of CD8+ IFNγ+ cells in the spleen of FL-treated and 
control Balb/c mice. Mice were treated with FL (10 µg) or PBS for 10 days (day -3 to 6). 
On day 0, all mice were injected with IAV (PR8 strain). On day 10, mice were 
euthanized and an ICS was conducted on splenocytes. Absolute number of CD8+ T cells 
was then calculated as described in the text. * denotes a significance difference, p < 0.05 
(PBS n=9, FL n=12). 
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Figure 13: Absolute number of peritoneal CD8+ IFNγ+ cells in FL-treated and 
control Balb/c mice. Mice were treated with FL (10 µg) or PBS for 10 days (day -3 to 6). 
On day 0, all mice were injected with IAV (PR8 strain). On day 10, mice were 
euthanized and an ICS assay was conducted on PECs and absolute number of flu-specific 
CD8+ T cells was calculated. N = 3 (three separate experiments, pooled PECs) 
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Figure 14: CTL-mediated killing of NP147-pulsed target cells following FL 
treatment. P815 target cells were pulsed with 51-chromium and NP147. Target cells were 
then incubated with splenocytes isolated from mice that had received PBS or FL 
treatment. * denotes a significance difference, p < 0.05 (PBS n= 4, FL n= 4) 
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Figure 15: CTL-mediated cytotoxicity exerted by splenocytes obtained from FL- 
and PBS-treated mice. Target cells were pulsed with 51-chromium and subdominant 
peptides. Target cells were then incubated with splenocytes (effector cells) isolated from 
mice that had received PBS or FL treatment. * denotes a significance difference, p < 0.05 
(PBS n= 4, FL n= 4) 
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against NP147. Figure 15 demonstrates that FL treatment increased the killing ability of 
CTLs against some subdominant peptides as well. 
3.8 The effect of FL on recall flu-specific CD8+ T cell responses 
  In order to determine if FL treatment increases the ability of CD8+ T cells to 
respond to secondary exposure of IAV, a different time course experiment was designed. 
For ten days, mice were given either FL or PBS treatment subcutaneously (day -3 to day 
6).  Similarly to previous experiments, on day 0, IAV (PR8 strain) was administered to all 
mice. Instead of performing an ICS seven days later, mice were allowed to recover from 
this viral inoculation (day 7 to day 29). However, on day 30, mice were once again 
injected with IAV (SEQ12 strain). Seven days later, an ICS assay was conducted on the 
spleens of these animals. It should be noted that SEQ12 was used for the secondary 
inoculation to avoid an established antibody response. SEQ12 maintains the same 
epitopes as PR8, but avoids antibody recognition due to its altered external protein coat 
(87). The ICS methodology and data analysis for this experiment and previously 
explained experiments remain identical. Figures 16 and 17 demonstrate the effect of FL 
treatment on CTL recall responses. Figure 16, which takes into consideration the 
percentage of CD8+ T cell response, shows a decrease in recall response across all 
epitopes. This is in agreement with Figure 17, which shows a decrease in the absolute 
number of epitope-specific CD8+ T cells across all epitopes. However, it is important to 
note that the ID hierarchy remains unchanged in recall experiments.  
3.9 The effect of FL on CTL responses to IAV in BL/6 mice 
  In order to determine whether or not the selectively enhancing effect of FL on 
IAV-specific CD8+ T cell responses is limited to one mouse strain (H-2d Balb/c) only, I  
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Figure 16: Frequencies of flu-specific CD8+ T cells following secondary exposure of 
FL- and PBS-treated mice. Mice were treated with FL (10 µg) or PBS for 10 days (day 
-3 to 6). On day 0, all mice were injected with IAV (PR8 strain). Mice were allowed to 
overcome this initial viral inoculum (day 7 to 29). On day 30, mice were re-exposed to 
IAV (SEQ12 strain). Seven days later, mice were euthanized and an ICS was conducted 
on splenocytes. * denotes a significance difference, p < 0.05 (PBS n=4 FL n=4) 
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Figure 17: Absolute number of flu-specific CD8+ T cells following secondary 
exposure in FL- and PBS-treated mice. Mice were treated with FL (10 µg) or PBS for 
10 days (day -3 to 6). On day 0, all mice were injected with IAV (PR8 strain). Mice were 
allowed to overcome this initial viral inoculum (day 7 to 29). On day 30, mice were re-
exposed to IAV (SEQ12 strain). Seven days later, mice were euthanized and an ICS was 
conducted on splenocytes and the absolute number of flu-specific CD8+ T cells was 
calculated as described in the text. * denotes a significance difference, p < 0.05 (PBS n=4 
FL n=4) 
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examined anti-IAV CD8+ T cell responses of H-2b C57BL/6 mice following their 
treatment with FL using a similar treatment regimen.  Mice were injected with FL or PBS 
for 10 days (day -3 to day 6). On day 0 of this experiment, BL/6 mice were injected with 
IAV (PR8 strain). Mice were then euthanized seven days later and an ICS assay for IFNγ 
was conducted using splenocytes obtained from the spleens of these animals. Previous 
studies have reported that IAV-specific CD8+ T cell responses in BL/6 mice are favoured 
towards two immunodominant peptides, namely NP366 and PA224 (50, 56). Weaker 
responses are found towards several subdominant epitopes. These are PB1-F262, PB1703, 
PB2198, NS2114, and M1128, in order of decreasing CD8+ T cell response they induce. A 
difference in the methodology is that since BL/6 mice possess an H-2b MHC background, 
their CD8+ T cells can only respond to cells presenting antigen with the same MHC (rule 
of MHC class restriction) (36). Therefore, DC2.4 cells, which share this H-2b MHC 
background, were used (86). As in Balb/c mice, the percentage and absolute number of 
CD8+ IFNγ+ are presented graphically (Figures 18 and 19). Figure 18, which illustrates 
the percentage of cognate CD8+ T cells within the spleen, shows no difference between 
PBS and FL treatment. This is contrary to the results I obtained in Balb/c mice (Figure 
10), which did show a selective increase in the percentage of CD8+ T cell responding to 
several epitopes. On the other hand, Figure 19 indicates an increase in the absolute 
number of some cognate CD8+ T cells, which is likely a reflection of increased overall 
splenic cellularity, due to FL treatment. Therefore, I found a large increase in the absolute 
number of CD8+ T cells responding towards both immunodominant epitopes in BL/6 
mice. It should be noted that the ID hierarchy did not change as a result of FL treatment.  
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Figure 18: Frequencies of CD8+ IFNγ+ cells in the spleens of FL-treated and control 
BL/6 mice. Mice were treated with FL (10 µg) or PBS for 10 days (day -3 to 6). On day 
0, all mice were injected with IAV (PR8 strain). On day 10, mice were euthanized and an 
ICS was conducted using splenocytes to determine the percentage of the double positive 
(CD8+ IFNγ+) cells, which represent epitope-specific CD8+ T cells. * denotes a 
significance difference, p < 0.05 (PBS n=8, FL n=8).  
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Figure 19: Absolute number of splenic CD8+ IFNγ+ cells in FL-treated and control 
BL/6 mice. Mice were treated with FL (10 µg) or PBS for 10 days (day -3 to 6). On day 
0, all mice were injected with IAV (PR8 strain). On day 10, mice were euthanized and an 
ICS was conducted on splenocytes. Absolute number of CD8+ T cells was then calculated 
as described in the text. * denotes a significance difference, p < 0.05 (PBS n=8, FL n=8). 
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In this study, the beneficial effects of FL treatment on CD8+ T cell responses to 
IAV were examined. Previous studies have illustrated the ability of FL treatment to 
enhance immune responses to other viral infections (79, 90). However, the effect of FL 
on cognate CD8+ T cell response to IAV has not been explored. In addition, it was not 
known whether treatment with FL affects the breadth of IAV-specific CD8+ T cell 
responses. In my initial experiments, the ability of FL to expand the two major DC 
populations, namely pDCs and cDCs was explored. As reported in the literature, a 10-day 
treatment schedule (10 µg daily) usually leads to splenomegaly as a result of expanding 
splenic populations (63, 85). This observation was confirmed during the treatment period 
with FL. I also demonstrated that both in vitro and in vivo, FL treatment effectively 
expands the population of both plasmacytoid and conventional dendritic cells.  
  Given important roles these DC subsets play in the context of viral immunity, 
future studies need to uncover which population contributes to the augmentation of IAV-
specific CD8+ T cell responses (if not both). Several studies have reported the presence 
of at least three subtypes of cDCs in the spleens of mice (76, 91). cDCs are of prime 
importance to anti-pathogen immunity due to their innate ability to uptake and present 
antigens to naïve T cells (36, 75, 76). All cDC subsets are CD11chigh (91) and as such, are 
not distinguishable based on the cell staining shown.  The cDC subsets are CD8+ DCs, 
CD4+ DCs and CD8-CD4- (double negative) DCs (91). It has been shown that CD8+ DCs, 
in particular, play a large role in the cross presentation of antigen (76, 91). Cross 
presentation is simply defined as the capture and presentation of antigen from exogenous 
sources that is mediated by professional APCs such as DCs. During cross presentation 
leading to cross priming, host APCs process and present antigens taken up from other 
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cells (92). For example, if a cell is infected with a virus but lacks the appropriate co-
stimulatory molecules, viral antigens or other materials from that infected cell can be 
taken up by DCs and presented via MHC class I to naïve T cells (36, 92).  DCs have high 
levels of co-stimulatory molecules such as B7-1 and B7-2 and can form stable and 
productive immunological synapses with naïve T cells, which is a prerequisite for their 
activation to activate naïve T cells (36, 37). With cross presentation having the ability to 
play a significant role in viral responses it would be beneficial to monitor if this specific 
CD8+ DC population is expanding. In the future, staining the splenocytes of FL-treated 
mice with a combination of CD11c, B220, CD4 and CD8 mAbs may provide a more 
accurate indication of which DC subset(s) is/are having the biggest contribution to CD8+ 
T cell responses to IAV.  
  In order to test the function of these CD8+ DCs during FL treatment a simple 
experiment can be suggested. The exact same experimental outline and timeline used in 
mice can be done in Batf3-/- mice. These mice are deficient in CD8+ DCs only (94) and, 
as such, comparing the responses between PBS and FL treatment groups between Batf3-/- 
and BL/6 mice will provide an accurate assessment of the effect of CD8+ DCs in 
promoting an increase in percentage and absolute number of epitope-specific CD8+ T 
cells. Although cDCs do possess an increased ability to activate naïve T cells, pDCs do 
have an important role in antiviral responses. As mentioned, pDCs possess TLRs 7 and 9, 
which are essential in the recognition of single standard RNA viruses and DNA viruses 
respectively (36, 84). Once these TLRs are activated by the presence of viral particles, 
pDCs secrete multiple cytokines, including large amounts of IFNα and IFNβ (36). In 
addition, the cytokines secreted by pDCs enhance the cross presentation ability of cDCs 
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(92). Given this information, it may be important to determine if the pDC population is 
having an effect directly or indirectly on CD8+ T cell responses to IAV. It is quite 
possible that the increased secretion of cytokines by pDC may create a microenvironment 
that promotes and enhances CD8+ cDC function. Nevertheless, for the purpose of this 
thesis, there is a clear expansion in both the DC populations.  
  My findings indicate that FL treatment increases both the percentage and the 
absolute numbers of CD8+IFNγ+ cells, which represent CD8+ T cells specific for multiple 
epitopes. This is a novel finding as far as the magnitude and breadth of IAV-specific 
CD8+ T cell response are concerned. By graphically representing the percentage of 
CD8+IFNγ+ cells, any changes in overall frequency of responding epitope-specific CD8+ 
T cells can be accurately recorded. Additionally, displaying the percentage of responding 
cells allows for an accurate comparison of responsiveness towards different IAV-derived 
peptides and the detection of any potential changes in the ID hierarchy of IAV. ID 
dictates that certain peptides, due to previously described factors; elicit a more robust 
CD8+ T cell response (IDD) in comparison with other subdominant determinants (SDD) 
(46 – 49). ID is a hurdle in the creation of effective vaccines that are designed to increase 
the CD8+ T cell response (46). Each virus has the ability to create tens of thousands of 
possible immunogenic peptides, however, significant CD8+ T cell responses are usually 
limited to few, sometimes one or two, IDDs. Having a strong immune response to only 
one or two possible peptides out of tens of thousands may not be very efficient, especially 
due to the potential ability of viral pathogens to easily mutate.  Therefore a treatment 
option that increases the CD8+ T cell response to various peptides of a pathogen is 
thought to be significantly beneficial. 
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In my study, FL treatment did increase the splenic frequency of responding cells 
to each epitope, in addition to the overall detection of flu-infected cells. In fact, the 
frequency of CD8+ T cells responding to immunodominant peptide NP147 and 
subdominant peptides NP39 and PB2289 increased significantly. However, FL treatment 
failed to increase peritoneal CD8+ T cell responses IAV-derived peptides. As mentioned, 
the responsiveness of peritoneal exudate cells (PECs) provides a picture of local CD8+ T 
cell responses to the viral inoculum that has been injected via the i.p. route. This is 
contrary to splenic CD8+ T cells that represent systemic responses. I found that CD8+ T 
cells detected in the peritoneal cavity and in the spleens of IAV-inoculated mice show 
different susceptibilities to FL treatment.  
  This can be due to a multitude of reasons, such as the differing antigen presenting 
cells present in each environment (95, 96). In addition, there are many other cell types 
among PECs, such as macrophages (95, 96), which may have an effect on the 
microenvironment through the release of various cytokines, which may alter the immune 
response as well. For instance, my experiments revealed a lower frequency of CD8+ T 
cells among PECs of FL-treated mice. This decrease in frequency may be due to an 
increase in other effector cells recruited to the peritoneal cavity as a result of FL 
treatment. Moreover, the peritoneal cavity contains a unique B cell subset, called B1 B 
cells (97). These innate-like B-lymphocytes may exhibit regulatory properties due to their 
ability to secrete significant amounts of interleukin (IL) 10 (97). As reported in the 
literature, IL-10 may have the ability to dampen the CD8+ T cell response (98). This may 
explain, at least partially, why FL treatment is not as effective in the peritoneal cavity. It 
should be noted that although FL treatment did increase the frequency of CD8+ T cells in 
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the spleen, the ID hierarchy did not change in either the splenic or peritoneal responses. 
Interestingly, the frequency of overall splenic CD8+ cell population (out of live cells) 
remained similar for both PBS and FL treatment groups. Therefore, an increase in the 
absolute number of CD8+ T cells is likely a reflection of an increase, at least in part, in 
the percentage of epitope-specific CD8+ T cells. In order to determine the absolute 
number of CD8+ T cells in the spleen and PECs, the absolute number of CD8+ cells was 
first calculated. This was accomplished by multiplying the percentage of CD8+ gated 
cells by the overall splenocyte count. From here, the absolute number of CD8+ cells was 
multiplied by the percentage of double positive cells (CD8+ IFNγ+) to effectively give the 
absolute number of IAV-specific CD8+ T cells. It is clear that FL-treated mice have 
increased numbers of epitope-specific CD8+ T cells in both the spleen and PECs. In fact, 
there was a significant increase in the absolute number of splenic CD8+ T cells 
responding to the immunodominant peptide NP147, NP39 and the flu-infected cells. When 
dealing with a viral infection, the absolute numbers of virus-specific CD8+ T cells 
obviously carry more weight than their frequencies do. The goal of a CD8+ vaccine is to 
increase the rate of viral clearance. This is not achieved through an increase in the 
percentage of cells, but rather by increasing the absolute number of effector cells. In this 
case, effector cells are epitope-specific CD8+ T cells, which lyse virally infected cells. In 
a patient, a high number of responding cells is crucial as it provides an improved ability 
to remove virally infected cells from the body and prevents morbidity and mortality. In 
fact, the results found in this portion of my thesis, which indicate FLs ability to increase 
the percentage and absolute number of CD8+ T cell response to IAV correlates well with 
the literature. Previous studies show that FL treatment has the ability to increase the 
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CD8+ T cell response to pathogens such as malaria parasite and listeria (99, 100). As 
such, the ability of FL treatment to increase the anti-IAV CD8+ T cell response coincides 
with these findings. 
  In my experimental system, IAV is injected directly into the peritoneal cavity. 
Although this system does allow the accurate assessment of the percentage and absolute 
number of epitope-specific CD8+ T cells, it does not completely represent productive 
infection with this virus. T cells can be activated through direct priming, usually when a 
DC is infected with the virus itself, or through cross priming (explained above). In the 
future, it may of interest to determine the effect of FL treatment on the activation of 
CD8+ T cells via direct or cross priming pathways. In order to test the effects of FL 
treatment on cross priming, the following experiment may be used. 
  One can infect a cell line with a H-2b background with IAV. Once the cell line is 
appropriately infected, the cells can be irradiated and washed to remove any excess viral 
particles on the surface of these cells. Also, incubation with an anti-hemagglutinin (anti-
HA) antibody will block any remaining viral particles on the surface of these cells. After 
anti-HA treatment, these flu infected cells can be washed, irradiated, and injected into 
Balb/c mice (H-2d) who have/will receive PBS or FL treatment 3 days prior to injection 
and 6 days post-injection. In this experiment CD8+ T cell activation is thought to be 
induced via cross priming (92, 103). This is due to three main reasons: i) the infected and 
injected cells are allogeneic to the host and therefore can not directly activate host T cells 
according to the rule of MHC class restriction; ii) gamma irradiation kills the virus and 
prevents its spread to other cells that could potentially induce direct priming; iii) the anti-
HA antibodies prevent any viral particles on the surface of the injected cells to be directly 
66 
 
recognized by host cells (92, 103). Following the same ICS procedure as above, the effect 
of FL treatment on cross priming and its ability to increase the frequency and absolute 
number of epitope-specific CD8+ T cells can be accurately measured.  
  As mentioned, when dealing with a viral infection, the absolute numbers of 
effector cells play a significant role. However, just as important is the efficiency of these 
effector cells at performing their designated tasks. The main effector function of CTLs 
lies in their ability to effectively kill virally infected cells thus preventing the further 
spread of the virus (36). When activated, CTLs release cytotoxic effector molecules such 
as perforin and granzymes eventually leading to apoptosis of the virally infected cell (36, 
43, 44). In addition, activated CTLs express surface protein FasL, which plays a role in 
inducing apoptosis of virally infected cells (43 – 45). In order to assess the cytotoxic 
effector function of CTLs the 51Cr release assay was used. As mentioned before, the goal 
of a CD8+ T cell vaccination is the promotion of viral clearance (cell death), as such; the 
51Cr release assay allows for accurate measurement of this function. While other CTL 
killing assays, such as Granzyme B ELISpot, have the advantage of directly measuring 
the number of cytokine-releasing CTLs, they fail to assess authentic killing function of 
CTLs. In addition, they may miss killing pathways not contributed by granzymes (e.g., 
the Fas-FasL pathway). My findings indicate that FL treatment enhances the killing 
function of these epitope-specific CTLs across all effector-to-target ratios. Not only did 
FL enhance the killing of target cells pulsed with the IDD, but it also enhanced the killing 
of target cells pulsed with subdominant epitopes. It should be noted that P815 cells were 
used as target cells during the chromium release assay for two main reasons. The first 
reason is the H-2d background of this mouse lymphoblast-like mastocytoma cell line 
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allows for syngeneic recognition of peptide:MHC I complexes according to the rule of 
MHC restriction (101). Therefore, these effector cells can lyse the virally infected target 
cells once recognized via MHC class I:peptide presentation.  Secondly, the P815 cell line 
is resistant to NK cell-mediated killing (101). NK cells, unlike CTLs, fail to express a 
TCR, but rather respond to cells that are stressed and are missing “self” markers (36). By 
using the P815 cell line during the 51Cr assay, one can conclude that the killing to be 
reported is done by epitope-specific CTLs, not by NK cells. The ability of FL to increase 
the percentage, absolute number and effector killing function of these CTLs is consistent 
with the hypothesis that DC mobilization by FL enhances various aspects of anti-IAV 
CD8+ T cell responses. 
  In order to determine the sustainability of FL treatment, I examined the effect of 
FL on IAV-specific CD8+ T memory responses. This experiment allowed for the 
comparison of primary and secondary CD8+ T cell responses in FL- or PBS-treated mice. 
To quickly recap, mice were administered PBS or FL during the prime period (day -3 to 
day 6) and received a PR8 inoculum on day 0. The resolution period was next (day 7 to 
day 29) as mice were allowed to recover from initial inoculations. On the first day of the 
boost period (Day 30 to Day 37) mice were injected with SEQ12. As mentioned in the 
results portion, SEQ12 maintains the same epitopes as PR8, but avoids antibody 
recognition due to its altered external protein coat (87). This enables the examination of 
recall CD8+ T cell responses to IAV without worrying about the ability of neutralizing 
Abs to remove viral particles before CD8+ T cells find an opportunity to mount a 
secondary response. Seven days after the secondary exposure, I examined CD8+ T cell 
responses to IAV in PBS- and FL-treated animals, similar to those in the primary 
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response experiments. Although further experiments are required to validate these results, 
FL treatment administered during the prime phase decreased the percentage and absolute 
number of epitope-specific CD8+ T cells. This result holds true for all epitopes tested, 
including the immunodominant peptide NP147. Interestingly, the ID hierarchy for IAV 
remains constant and similar to the pattern established during the primary response. 
Although these results were not quite what I expected, they may be explained, at least 
theoretically, by what we know about the function of FL. Contrasting to the primary ICS, 
the absolute number count of splenocytes between the two treatment groups showed no 
change (data not shown). As such, it is possible that the effect of FL treatment lasts for a 
certain duration, as seen in the primary response, but given an extended period the effect 
fades.  
  This however, does not seem to be the case as indicated by Mosley et al, who 
have reported the ability of FL treatment in the expansion of effector-memory T cells 
(102). Using the same FL dosage scheme as in my experiments, Mosley et al, illustrated 
that FL treatment increases the percentage and absolute number of effector memory cells 
(102). The staining for CD44, which is a standard effector-memory cell marker, indicated 
effector memory cells (102). For the future of this project, a repeat of this experiment 
must be conducted, as there is evidence for the role of FL in the development of effector-
memory cells.  
  With the possibility of FL treatment enhancing the development of effector-
memory CD8+ T cells, it would be of interest to treat mice with FL or PBS as in the 
primary response, and then during the resolution period, stain for CD127 (IL-7 receptor α 
chain) and KLRG1 (103). It would be important to determine if FL treatment enhances 
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the frequency of memory CD8+ T cell precursors (CD127highKLRG1low) or short-lived 
effectors (CD127lowKLRG1high) (103). Additionally, the administration of FL throughout 
the entire 37-day process or just during the final boost period can be conducted to 
determine if there is any change in the percentage or absolute number of epitope-specific 
CD8+ T cells following these treatment regimens.  
  In the final portion of this project, the exploration on the effect of FL treatment in 
BL/6 mice was conducted in order to examine whether the increase in percentage and 
absolute number of CD8+ T cells is mouse-strain-specific. Although, FL treatment did not 
increase the percentage of epitope-specific CD8+ T cells, it did increase the absolute 
numbers of these cells across all epitopes. Even though this experiment was conducted 
once with 4 mice per group, the absolute number of CD8+ T cells responding to the IDD 
(NP366) for IAV in the BL/6 reached statistical significance. Although the percentage of 
IAV-specific CD8+ T cells in BL/6 mice did not change significantly due to FL 
treatment, the absolute number, which is important in any viral infection, did 
dramatically increase.  
  The difference in the responsiveness between the two strains, BL/6 and Balb/c, 
may be due to their natural immune responses. BL/6 mice are traditionally known to 
favour a TH1 skewed immune response, which is usually characterized by the functions 
of several proinflammatory cytokines such as IFNγ (102). On the contrary, Balb/c mice 
are TH2-dominant, which is more anti-inflammatory through the release of cytokines 
such as interleukin (IL) 4 and 5 (102). Given this, the effect of FL treatment, which has 
been shown to increase the percentage and absolute number of CD8+ IFNγ releasing T 
cells, may be more pronounced in a Balb/c strain which posses an inherent deficiency in 
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this type of response.  
  Although the exact mechanism underlying the beneficial effect of FL treatment 
effects on CD8+ T cell antiviral responses remains to be uncovered it is clear that this 
treatment option is a promising therapeutic candidate in the fight against IAV. The results 
illustrated in this thesis have implications with regard to the FL’s potential adjuvanticity 
in effective antiviral treatment and vaccination. ID is an important factor to consider in 
rational vaccine design. IAV mutations may cause their antigenic epitopes to be no longer 
detectable by CD8+ T cells and thus inhibiting the ability to eliminate the virus from the 
infected host (18, 19).  FL treatment has shown to broaden and increase the magnitude of 
CD8+ T cell responses to multiple epitopes of IAV, which allow for a more efficient 
CD8+ T cell response. As previously described, current vaccination attempts have 
focused on the neutralization of surface proteins HA and NA (16, 18, 19). Nonetheless, 
these proteins are under constant immune pressures and are constantly changing (18, 19, 
103). However, FL has shown to augment the CD8+ T cell response to relatively 
conserved internal viral antigens. For example, the nucleoprotein gene in IAV has a 
conservation rate of 90% in varying IAV subtypes (H1N1, H2N2 and H3N2) (103).  
Promoting an increased response to these segments may protect individuals from 
emerging reassorted IAV viruses.  
  From hospitalizations and death to economic burden, IAV has been and will 
continue to be a constant hindrance on our society. With the continuously expanding 
reservoir of possible IAV mixing and high mutation rates, attempts to develop an 
effective and efficient treatment option have not been successful. As such, the idea of 
therapeutic agents, which have the ability to alter immune responses to viral antigens, is 
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being explored. My experimental findings reveal the prospective therapeutic benefits of 
FL treatment in the framework of a CD8+ T cell vaccine or other antiviral treatments.  
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